The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Open accessAbstract
OBJECTIVE: The authors conducted a systematic review and meta-analysis of ketamine and other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major depression. METHOD: Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomized clinical trials of NMDA antagonists in the treatment of depression. Primary outcomes were rates of treatment response and transient remission of symptoms. Secondary outcomes included change in depression symptom severity and the frequency and severity of dissociative and psychotomimetic effects. Results for each NMDA antagonist were combined in meta-analyses, reporting odds ratios for dichotomous outcomes and standardized mean differences for continuous outcomes. RESULTS: Ketamine (seven trials encompassing 147 ketamine-treated participants) produced a rapid, yet transient, antidepressant effect, with odds ratios for response and transient remission of symptoms at 24 hours equaling 9.87 (4.37-22.29) and 14.47 (2.67-78.49), respectively, accompanied by brief psychotomimetic and dissociative effects. Ketamine augmentation of ECT (five trials encompassing 89 ketamine-treated participants) significantly reduced depressive symptoms following an initial treatment (Hedges' g=0.933) but not at the conclusion of the ECT course. Other NMDA antagonists failed to consistently demonstrate efficacy; however, two partial agonists at the NMDA coagonist site, d-cycloserine and rapastinel, significantly reduced depressive symptoms without psychotomimetic or dissociative effects. CONCLUSIONS: The antidepressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glutamate-modulating strategies; however, the ineffectiveness of other NMDA antagonists suggests that any forthcoming advances will depend on improving our understanding of ketamine's mechanism of action. The fleeting nature of ketamine's therapeutic benefit, coupled with its potential for abuse and neurotoxicity, suggest that its use in the clinical setting warrants caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of note, however, rapastinel, another drug that reverses synaptic plasticity deficits and exhibits antidepressant-like effects in rodent models 36,37 , has been studied in 3 clinical trials to date with relatively weak evidence for its efficacy 38 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [38]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ketamine, an antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor (an ionotropic glutamate receptor), was shown to exhibit rapid onset and robust, short-term antidepressant effect in patients with treatment-resistant depression (TRD) [1–3].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Racemic ketamine was obtained from the Yale-New Haven Hospital Pharmacy and administered intravenously by constant infusion over 40 minutes at a dose of 0.5mg/kg, which has consistently been shown to have robust and rapid antidepressant effects 7,8 , and is typically used clinically.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [8]
In the citing paper
“This is supported by the finding that other NMDA receptor antagonists such as memantine, lanicemine and nitrous oxide do not exert a consistent antidepressant effect in RCTs.90”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [90]
In the citing paper
“Ketamine's antidepressant effects compared to placebo controls are further supported by several thorough meta-analyses [134-136].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [134]
In the citing paper
“This literature leads to the conclusion that while alternative NMDAR channel-blocking antagonists may exert clinical antidepressant actions, such actions are not of the same time frame or magnitude as those exerted by ketamine.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [99]
In the citing paper
“However, clinical trials indicate that these alternative NMDAR antagonists, lack the rapid, robust and/or long-lasting antidepressant actions of ketamine in humans 99.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 259
RetractedBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053
Research works printed but not linked: 6
Cited by
Sorted by citations
Items 201–300 of 599
Ketamine metabolite pilot study in a suicidal depression trial
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Parris, M. S., Burke, A. K., Suckow, R. F., Cooper, T. B., & Mann, J. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.08.005 · Cited by 41
Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition
Lüscher, B., Feng, M., & Jefferson, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.03.002 · Cited by 41
The role of immunomodulators in treatment-resistant depression: case studies
Beckett, C. W., & Niklison-Chirou, M. V. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01147-6 · Cited by 43
Novel treatments for anorexia nervosa: Insights from neuroplasticity research
Keeler, J. L., Kan, C., Treasure, J. L., & Himmerich, H. (2023) · European Eating Disorders Review · doi:10.1002/erv.3039 · Cited by 41
Hales, C. A., Houghton, C. J., & Robinson, E. S. J. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.09.008 · Cited by 41
Ketamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 41
MECP2 and the biology of MECP2 duplication syndrome
D’Mello, S. R. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15331 · Cited by 42
Plasticity of synapses and reward circuit function in the genesis and treatment of depression
Thompson, S. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01422-1 · Cited by 40
Conley, A. A., Norwood, A. E. Q., Hatvany, T. C., Griffith, J. D., & Barber, K. E. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05825-8 · Cited by 39
Keeler, J. L., Robinson, L., Keeler-Schäffeler, R., Dalton, B., Treasure, J. L., & Himmerich, H. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.2015432 · Cited by 39
KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?
Wilkinson, S. T., & Sanacora, G. (2016) · Depression and Anxiety · doi:10.1002/da.22498 · Cited by 41
Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
Lima, T. D. M., Visacri, M. B., & Aguiar, P. M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03216-8 · Cited by 43
Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders
Wilkinson, S. T., & Sanacora, G. (2017) · JAMA · doi:10.1001/jama.2017.10697 · Cited by 38
What Is New about New Antidepressants?
Dubovsky, S. L. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000488945 · Cited by 37
Addictive potential of novel treatments for refractory depression and anxiety
Kolar, D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167538 · Cited by 37
Hashimoto, K., Zhao, M., Zhu, T., Wang, X., & Yang, J. (2024) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2024.07.001 · Cited by 38
Godlewska, B. R. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.010 · Cited by 38
Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders
Sanacora, G., Heimer, H., Hartman, D., Mathew, S. J., Frye, M., Nemeroff, C. B., & Beale, R. R. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.193 · Cited by 36
Self-citationUse of Ketamine in Elderly Patients with Treatment-Resistant Depression
Ribeiro, C. M. D. F., & Riva‐Posse, P. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0855-x · Cited by 36
Pałucha-Poniewiera, A. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.02.011 · Cited by 36
Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs
Boros, F. A., & Vécsei, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1813716 · Cited by 38
Intranasal esketamine: From origins to future implications in treatment-resistant depression
Sanders, B. J., & Brula, A. Q. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.020 · Cited by 37
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Ragnhildstveit, A., Slayton, M., Jackson, L. K., Brendle, M., Ahuja, S., Holle, W., Moore, C., Sollars, K., Seli, P., & Robison, R. (2022) · Brain Sciences · doi:10.3390/brainsci12030382 · Cited by 35
Best, S. R. D., Pavel, D. G., & Haustrup, N. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02187 · Cited by 38
Roy, A. V., Thai, M., Klimes‐Dougan, B., Schreiner, M. W., Mueller, B. A., Albott, C. S., Lim, K. O., Fiecas, M. J. A., Tye, S. J., & Cullen, K. R. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120928203 · Cited by 38
Hua, H., Huang, C., Liu, H., Xu, X., Xu, X., Wu, Z., Liu, C., Wang, Y. Y., & Yang, C. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109272 · Cited by 37
Cowen, P. J. (2019) · Cambridge University Press eBooks · doi:10.1017/9781911623175.002 · Cited by 34
Rodolico, A., Cutrufelli, P., Francesco, A. D., Aguglia, A., Catania, G., Concerto, C., Cuomo, A., Fagiolini, A. M., Lanza, G., Mineo, L., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1325399 · Cited by 40
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J. M., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N., et al. (2017) · Nature · doi:10.1038/nature22085 · Cited by 34
Zarate, C. A., & Machado‐Vieira, R. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.249 · Cited by 33
A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression
Park, L. T., Lener, M. S., Hopkins, M., Iadorola, N., Machado‐Vieira, R., Ballard, E. D., Nugent, A. C., & Zarate, C. A. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000693 · Cited by 34
Ketamine effects on anxiety and fear-related behaviors: Current literature evidence and new findings
Silote, G. P., de Oliveira, S. F. S., Ribeiro, D. E., Machado, M. S., Andreatini, R., Joca, S. R. L., & Beijamini, V. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109878 · Cited by 33
Zhang, M. W., Hong, Y. X., Husain, S. F., Harris, K. M., & Ho, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173202 · Cited by 33
Zhang, K., Toki, H., Fujita, Y., Ma, M., Chang, L., Qu, Y., Harada, S., Nemoto, T., Mizuno‐Yasuhira, A., Yamaguchi, J., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5017-2 · Cited by 32
Amat-Foraster, M., Jensen, A. A., Plath, N., Herrik, K. F., Celada, P., & Artigas, F. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.022 · Cited by 34
Antidepressant mechanisms of ketamine’s action: NF-κB in the spotlight
Sokołowska, P., Karbownik, M. S., Jóźwiak-Bębenista, M., Dobielska, M., Kowalczyk, E., & Wiktorowska‐Owczarek, A. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115918 · Cited by 37
Ketamine for Treatment-Resistant Depression
Zarate Jr, C. A., & Mathew, S. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0 · Cited by 34
Morris, P. J., Burke, R. D., Sharma, A. K., Lynch, D. C., Lemke-Boutcher, L. E., Mathew, S., Elayan, I., Rao, D. B., Gould, T. D., Zarate, C. A., et al. (2021) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2021.106993 · Cited by 33
Ragnhildstveit, A., Jackson, L. K., Cunningham, S. R., Good, L., Tanner, Q., Roughan, M., & Henrie-Barrus, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.764112 · Cited by 34
Slovik, M., Rosin, B., Moshel, S., Mitelman, R., Schechtman, E., Eitan, R., Raz, A., & Bergman, H. (2017) · Journal of Neurophysiology · doi:10.1152/jn.00765.2016 · Cited by 31
Wei, Y., Chang, L., & Hashimoto, K. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.010 · Cited by 30
WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?: Editorial
Newport, D. J., Schatzberg, A. F., & Nemeroff, C. B. (2016) · Depression and Anxiety · doi:10.1002/da.22535 · Cited by 30
Self-citationAmat-Foraster, M., Celada, P., Richter, U., Jensen, A. A., Plath, N., Artigas, F., & Herrik, K. F. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107745 · Cited by 33
Vankawala, J., Naples, G., Avila-Quintero, V. J., Ramírez, K. L., Flores, J. M., Bloch, M. H., & Dwyer, J. B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.549080 · Cited by 30
Davis, G. L., Minerva, A. R., Lario, A., Simmler, L. D., Rodríguez, C. I., & Gunaydin, L. A. (2021) · Nature Communications · doi:10.1038/s41467-021-26247-2 · Cited by 35
Ray-Griffith, S. L., Eads, L. A., Han, X., Golden, K., & Stowe, Z. N. (2017) · Journal of Ect · doi:10.1097/yct.0000000000000413 · Cited by 30
Zhang, K., Ma, M., Dong, C., & Hashimoto, K. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy065 · Cited by 30
Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine
Zanos, P., Moaddel, R., Morris, P. J., Wainer, I. W., Albuquerque, E. X., Thompson, S. M., Thomas, C. J., Zarate, C. A., & Gould, T. D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.08.039 · Cited by 31
Ketamine: stimulating antidepressant treatment?
Malhi, G. S., Byrow, Y., Cassidy, F., Cipriani, A., Demyttenaere, K., Frye, M. A., Gitlin, M., Kennedy, S. H., Ketter, T. A., Lam, R. W., et al. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.002923 · Cited by 29
Self-citationThe Role of Psychedelics and Counseling in Mental Health Treatment
Curtis, R., Roberts, L. C., Graves, E. G., Rainey, H. T., Wynn, D. D., Krantz, D., & Wieloch, V. (2020) · Journal of Mental Health Counseling · doi:10.17744/mehc.42.4.03 · Cited by 35
Chaki, S., & Fukumoto, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061270 · Cited by 29
Okada, M., Fukuyama, K., Nakano, T., & Ueda, Y. (2019) · Biomolecules · doi:10.3390/biom9110746 · Cited by 29
Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models
Kyzar, E. J., & Kalueff, A. V. (2016) · Zebrafish · doi:10.1089/zeb.2016.1251 · Cited by 31
Association between depression subtypes and response to repeated‐dose intravenous ketamine
Wang, C., Zhou, Y., Zheng, W., Liu, W., Zhan, Y., Li, H., Chen, L., Zhang, B., Walter, M., Li, M., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13096 · Cited by 30
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Henter, I. D., SOUSA, R. T. D., Gold, P. W., Brunoni, A. R., Zarate, C. A., & Machado‐Vieira, R. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1253472 · Cited by 29
Pham, T. H., Defaix, C., Nguyen, T. M. L., Mendez‐David, I., Tritschler, L., David, D. J. P., & Gardier, A. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172913 · Cited by 30
Registered clinical trials investigating ketamine for psychiatric disorders
Peyrovian, B., McIntyre, R. S., Phan, L., Lui, L. M. W., Gill, H., Majeed, A., Chen-Li, D. C. J., Nasri, F., & Rosenblat, J. D. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.03.020 · Cited by 27
Herrera-Meléndez, A. L., Stippl, A., Aust, S., Scheidegger, M., Seifritz, E., Heuser, I., Otte, C., Bajbouj, M., Grimm, S., & Gärtner, M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.017 · Cited by 31
Fujita, Y., Hashimoto, Y., Hashimoto, H., Chang, L., & Hashimoto, K. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173954 · Cited by 26
López‐Díaz, Á., Fernández-González, J. L., Luján-Jiménez, J. E., Rus, S. G., & Gutiérrez-Rojas, L. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316675578 · Cited by 27
Zhu, X., Zhang, F., You, Y., Wang, H., Yuan, S., Wu, B., Zhu, R., Liu, D., Yan, F., & Wang, Z. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01180-6 · Cited by 26
Osanai, H., & Tateno, T. (2016) · Hearing Research · doi:10.1016/j.heares.2016.06.012 · Cited by 28
Deletion of serine racemase confers D-serine –dependent resilience to chronic social defeat stress
Dong, C., Zhang, J., Ren, Q., Ma, M., Qu, Y., Zhang, K., Yao, W., Ishima, T., Mori, H., & Hashimoto, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.03.008 · Cited by 26
Larrea, A., Sánchez-Sánchez, L., Díez-Martín, E., Elexpe, A., Torrecilla, M., Astigarraga, E., & Barreda‐Gómez, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061727 · Cited by 28
Beyond serotonin: newer antidepressants in the future
Rakesh, G., Pae, C., & Masand, P. S. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341310 · Cited by 26
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C. R., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19203 · Cited by 29
Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites
Ago, Y., Yokoyama, R., Asano, S., & Hashimoto, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109313 · Cited by 24
The Association of Serum and Dietary Magnesium with Depressive Symptoms
Chou, M.-H., Yang, Y. K., Wang, J., Lin, C., & Lin, S. (2023) · Nutrients · doi:10.3390/nu15030774 · Cited by 25
A review of the pharmacological action and mechanism of natural plant polysaccharides in depression
Yang, Y., Li, C.-X., Zhang, R., Shen, Y. H., Xu, X., & Yu, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1348019 · Cited by 30
Chang, L., Toki, H., Qu, Y., Fujita, Y., Mizuno‐Yasuhira, A., Yamaguchi, J., Chaki, S., & Hashimoto, K. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy053 · Cited by 25
New agents and perspectives in the pharmacological treatment of major depressive disorder
Sanches, M., Quevedo, J., & Soares, J. C. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110157 · Cited by 26
Translational Assessments of Reward Responsiveness in the Marmoset
Wooldridge, L. M., Bergman, J., Pizzagalli, D. A., & Kangas, B. D. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa090 · Cited by 27
The neurobiology of depression
Binakaj, Z., Stojkov, S., Gafić, E., Čongo, S., Đurić, S., & Binakaj, E. (2019) · Timocki medicinski glasnik · doi:10.5937/tmg1903118b · Cited by 25
Ketamine Mechanism of Action: Separating the Wheat from the Chaff
Gould, T. D., Zanos, P., & Zarate, C. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.210 · Cited by 24
Astroglial Mechanisms of Ketamine Action Include Reduced Mobility of Kir4.1-Carrying Vesicles
Stenovec, M., Božić, M., Pirnat, S., & Zorec, R. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02744-1 · Cited by 25
Yokoyama, R., Ago, Y., Igarashi, H., Higuchi, M., Tanuma, M., Shimazaki, Y., Kawai, T., Seiriki, K., Hayashida, M., Yamaguchi, S., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02419-6 · Cited by 26
Ketamine as a rapid antidepressant: the debate and implications
Ho, R., & Zhang, M. W. (2016) · BJPsych Advances · doi:10.1192/apt.bp.114.014274 · Cited by 25
Niciu, M. J., Iadarola, N. D., Banerjee, D., Luckenbaugh, D. A., Park, M., Lener, M. S., Park, L., Ionescu, D. F., Ballard, E. D., Brutsché, N. E., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117732514 · Cited by 23
Inkster, B., Zai, G. C., Lewis, G., & Miskowiak, K. W. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0270-z · Cited by 23
Phillips, J. L., Jaworska, N., Kamler, E., Bhat, V., Blier, J., Foster, J. A., Hassel, S., Ho, K. T., McMurray, L., Milev, R. V., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02672-3 · Cited by 24
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 24
Grieco, S. F., Cheng, Y., Eldar-Finkelman, H., Jope, R. S., & Beurel, E. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.08.008 · Cited by 22
Case Report: Ketamine for Pain and Depression in Advanced Cancer
Sexton, J., Atayee, R. S., & Bruner, H. C. (2018) · Journal of Palliative Medicine · doi:10.1089/jpm.2017.0551 · Cited by 22
Lipsitz, O., McIntyre, R. S., Rodrigues, N. B., Kaster, T. S., Cha, D. S., Brietzke, E. M., Gill, H., Nasri, F., Lin, K., Subramaniapillai, M., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110126 · Cited by 23
Brenna, C. T. A., Goldstein, B. I., Zarate, C. A., & Orser, B. A. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005037 · Cited by 23
Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients
Vidal, S. I., Jermann, F., Aubry, J., Richard-Lepouriel, H., & Kosel, M. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001305 · Cited by 22
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodríguez, C. I., Kalin, N. H., & McDonald, W. M. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19104 · Cited by 28
Self-citationLevinta, A., Meshkat, S., McIntyre, R. S., Ho, C., Lui, L. M. W., Lee, Y. L., Mansur, R. B., Teopiz, K. M., Rodrigues, N. B., Vincenzo, J. D. D., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.050 · Cited by 22
S -ketamine compared to etomidate during electroconvulsive therapy in major depression
Zavorotnyy, M., Kluge, I., Ahrens, K., Wohltmann, T., Köhnlein, B., Dietsche, P., Dannlowski, U., Kircher, T. T. J., & Konrad, C. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0800-3 · Cited by 21
Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders
Haroon, E., & Miller, A. H. (2017) · Modern trends in psychiatry · doi:10.1159/000470805 · Cited by 22
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2017) · Chronic Stress · doi:10.1177/2470547017743511 · Cited by 23
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19030273 · Cited by 21
Subramaniapillai, M., Carmona, N. E., Rong, C., & McIntyre, R. S. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/rmcintyre · Cited by 21
A systematic review of ketamine for the treatment of depression among older adults
Gupta, A., Dhar, R., Patadia, P., Funaro, M. C., Bhattacharya, G., Farheen, S. A., & Tampi, R. R. (2020) · International Psychogeriatrics · doi:10.1017/s1041610220000903 · Cited by 21
Ketamine for Depression: An Update
Murrough, J. W. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.005 · Cited by 20
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression
Sakurai, H., Dording, C., Yeung, A., Foster, S., Jain, F., Chang, T., Trinh, N.-H., Bernard, R., Boyden, S., Iqbal, S. Z., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.065 · Cited by 20
“, 2017), the limited efficacy of current drug treatments for depression represents an extraordinary need for discovering and applying novel antidepressant mechanisms beyond the monoamines (Papakostas and Ionescu, 2015; Newport et al., 2015; Chang and Fava, 2010).”
BackgroundChaki, S. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.03.004 · Cited by 21
Lineham, A., Avila-Quintero, V. J., Bloch, M. H., & Dwyer, J. B. (2023) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2022.0086 · Cited by 20
Spies, M., Klöbl, M., Höflich, A. S., Hummer, A., Vanicek, T., Michenthaler, P., Kranz, G. S., Hahn, A., Winkler, D., Windischberger, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46702-x · Cited by 22
Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review
Memon, R. I., Naveed, S., Faquih, A. E., Fida, A., Abbas, N., Chaudhary, A. M. D., & Qayyum, Z. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09830-6 · Cited by 22
Metadata
- Authors
- Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments
- Affiliations
- University of Miami (US)
- University of Iowa (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2015-10-01
- Volume
- 172
- Issue
- 10
- Pages
- 950-966
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2111728433
- Semantic Scholar
- 1554f1974f06fcabaaf6be07d58e1ebf23572172
- Cited by
- 598
- References
- 177
- Citations by year
- 2026: 27 · 2025: 36 · 2024: 37 · 2023: 50 · 2022: 53 · 2021: 65 · 2020: 62 · 2019: 65 · 2018: 71 · 2017: 64 · 2016: 62 · 2015: 5
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Foundation for Suicide Prevention
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Teva Pharmaceutical Industries
- Brown University
- Celgene
- University of Miami
- Emory University
- Sunovion
- National Alliance for Research on Schizophrenia and Depression
- OPKO Health
- University of Oxford
- Mitsubishi Tanabe Pharma Corporation
- H. Lundbeck A/S
- National Institutes of Health
- Health Resources and Services Administration
- School of Medicine, Emory University
- Allergan
- Leonard M. Miller School of Medicine
- Roy J. and Lucille A. Carver College of Medicine, University of Iowa
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, NMDA receptor antagonists, major depressive disorder, antidepressant efficacy, rapid-acting antidepressants, D-cycloserine, psychotomimetic effects, dissociative effects, glutamate modulation, treatment response, remission
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
